by Ciapponi A, Barreira F, Perelli L, Bardach A, Gascón J, Molina I, Morillo C, Prado N, Riarte A, Torrico F, Ribeiro I, Villar JC, Sosa-Estani S. PLOS Neglected Tropical Diseases 2020;14(8): e0008529. doi: 10.1371/journal.pntd.0008529
Summary: An optimal trypanocidal therapy is required for Chagas disease that achieves the best possible compliance. Some studies suggest that a simple fixed-dose scheme of benznidazole could be equivalent to the dose adjusted by weight for the treatment of adults seropositive to T. cruzi without clinically evident chronic Chagas cardiomyopathy. The authors conducted a rigorous systematic review and meta-analysis of randomized controlled trials by reviewing and analyzing the totality of available literature on the subject. Although they did not find direct evidence addressing this question, it appears that an adjusted dose is probably equivalent in terms of important safety and efficacy outcomes, while the effect on critical outcomes is uncertain. The authors are now conducting an individual patient data network meta-analysis.
